Novo Nordisk A/S/ DK0062498333 /
14.08.2023 11:58:16 | Изменение - | Объем сделки | Бид9:03:22 | Предложение17:13:24 | Рыночная капитализация | Дивидендная доходность | Коэффициент Цена/Доход |
---|---|---|---|---|---|---|---|
83.20EUR | - | 2 Оборот: 166.40 |
-Величина цены спроса: - | -Величина цены предложения: - | 415.87 млрдEUR | - | - |
Newsfile Corp
4:49
Tradewave Capital Plc Solidifies Its Position in Financial Markets with Vienna Stock Exchange Listin...
GlobeNewswire
4:38
Stockholder Alert: Robbins LLP Informs Investors that a Class Action Against Teladoc Health, Inc. (T...
Newsfile Corp
4:19
PaleBlueDot Launches $EARTH Token: A Unique Cryptocurrency with a Mission for Global Sustainability
GlobeNewswire
3:00
Volvo Trucks North America and Volvo Financial Services Launch Volvo on Demand to Accelerate Battery...
GlobeNewswire
3:00
TREACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Treace Medical Concepts, Inc. on Behalf o...
GlobeNewswire
3:00
GROCERY OUTLET ALERT: Bragar Eagel & Squire, P.C. is Investigating Grocery Outlet Holding Corp. on B...
GlobeNewswire
3:00
VESTIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Again...
GlobeNewswire
2:25
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
2:00
AST Mining Unveils Free Cloud Mining, Paving the Way for Seamless Crypto Investment in 2024.
GlobeNewswire
2:00
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Inari Medical, Inc. Investors to Secure Counsel Be...
GlobeNewswire
1:46
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница